Gland Pharma (NSE:GLAND) Construction In Progress: ₹3,422 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
83 GF Score
Price ₹2,314.80
GF Value ₹2,125.65
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Construction In Progress?

Gland Pharma NSE:GLAND -0.49% 83 Construction In Progress is ₹3,422 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,125.65 (Fairly Valued). The stock has 6 warning signs investors should review.

Gland Pharma's quarterly construction in progress declined from Sep. 2025 (₹2,089 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹3,422 Mil).

Gland Pharma's annual construction in progress declined from Mar. 2024 (₹2,787 Mil) to Mar. 2025 (₹1,817 Mil) but then increased from Mar. 2025 (₹1,817 Mil) to Mar. 2026 (₹3,422 Mil).

Gland Pharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Construction In Progress Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only 2,272.39 2,401.77 2,787.33 1,816.57 3,421.79

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,816.57 0.00 2,088.82 0.00 3,421.79
NSE:GLAND
83GF Score
Gland Pharma Ltd NSE:GLAND
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹3,422 Mil mean?
Gland Pharma (NSE:GLAND) has a Construction In Progress of ₹3,422 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Construction In Progress too high?
Gland Pharma's current Construction In Progress is ₹3,422 Mil. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Construction In Progress compare to ZTS?
Gland Pharma's Construction In Progress of ₹3,422 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Gland Pharma and its competitors. Gland Pharma's current Construction In Progress is ₹3,422 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,125.65, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current Construction In Progress is ₹3,422 Mil. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Construction In Progress is ₹3,422 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,125.65. GuruFocus considers Gland Pharma to be Fairly Valued.

Key valuation signals for NSE:GLAND:

  • Construction In Progress: ₹3,422 Mil
  • GF Value™: ₹2,125.65 vs. price of ₹2,314.80 (8.9% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score

Get the complete analysis for NSE:GLAND

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,314.80
Price
₹2,125.65
GF Value